Genprex

Videos

Genprex’s C-Suite Interview with Noble Capital Markets

Noble Capital Markets’ Senior Research Analyst, Robert LeBoyer, sits down with Genprex President & CEO, Rodney Varner, for this exclusive interview. Recorded on April 22, 2021.

Learn More

Genprex presents positive preclinical data for lung cancer drug REQORSA at AACR annual meeting

Genprex CEO, Rodney Varner, tells Proactive its collaborators have presented positive preclinical data for the combination of REQORSA in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC), as well as for REQORSA in combination with targeted therapies.

Varner says the data were presented in two presentations at the 2021 American Association of Cancer Research (AACR) annual meeting. The positive data is helpful for Genprex’s plan to launch a pair of upcoming clinical trials.

Learn More

CEORoadshow Interview with Rodney Varner, CEO of Genprex, Inc. (NASDAQ: GNPX)

Rodney Varner, President and CEO of Genprex, joins CEO Roadshow’s Mike Elliott to talk about the company’s gene therapies for cancer and diabetes.

Learn More

AACR 2021 – TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robust antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice – Meraz

The triple combination of chemotherapy, immunotherapy (immune checkpoint blockade) and REQORSA demonstrated strong antitumor efficacy and induced robust antitumor immunity in KRAS-LKB1 (KL)-mutant NSCLC in clinically relevant humanized mice models.

Learn More

Dr. George Gittes – Paradigm Shifts In Diabetes And Pediatric Medicine

Dr. George Gittes, the inventor of the diabetes gene therapy, GPX-002, discusses paradigm shifts in diabetes and pediatric medicine with Progress, Potential, and Possibilities’ Ira S. Pastor.

Learn More

Genprex’s drug REQORSA in cold storage, ready for upcoming combination trials

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive it has met the necessary specifications and passed the final release tests for its first manufacturing run of REQORSA immunogene therapy in advance of non-small cell lung cancer (NSCLC) clinical trials.

Learn More

Genprex launches new branding for its lead drug REQORSA in preparation for upcoming studies

Genprex, Inc. (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based group has launched new branding for the upcoming oncology clinical trials combining its lead drug candidate REQORSA with AstraZeneca’s Tagrisso and separately with Merck’s Keytruda for the treatment of non-small cell lung cancer (NSCLC).

Learn More

Genprex Participates in Noble Capital Markets’ C-Suite Interview Series

Genprex participates in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek, led by Noble Capital Markets Biotechnology Analyst Ahu Demir, Ph.D.

Learn More

Genprex’s CEO Appears on the Big Biz Show for a Second Time

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, participates in a live interview with the “Big Biz Show” for a second time, providing details on its lead drug candidate for NSCLC, its diabetes gene therapy and what lies ahead in the next 18 months in the midst of COVID-19.

Learn More

Genprex reveals slew of recent milestones as it plans for upcoming clinical trials

Genprex, Inc. (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive’s Christine Corrado about the Texas-based biotechnology company’s most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as Oncoprex. What’s more, its ramping up the production of its drug for upcoming clinical trials, and the company has joined the Russell 3000 index.

Learn More